Analyst Conference Summaries

Biotechnology Investor Aids

ImmunoGen
IMGN

conference date: May 3, 2019 @ 5:00 AM Pacific Time

ImmunoGen Price Run-Up Driven by Potential Trial Data [Feb. 6, 2018 at SA]

AML Therapies, Part 2: Agios and Immunogen [September 29, 2016 at Seeking Alpha]

ImmunoGen Oversold Despite Strong Pipeline [July 7, 2016 at Seeking Alpha]

2019
ImmunoGen
Q1 2019
May 3, 2019
2018
ImmunoGen
Q4 2018
May 4, 2018
July 27, 2018
Nov. 2, 2018
Feb. 8, 2018
2017
May 5, 2017
July 28, 2017
Nov. 3, 2017
Feb. 9, 2018
2016
04/29/2016
08/04/2016
10/28/2016
02/17/2017

Immunogen (IMGN) is a clinical-stage biotechnology company specializing in ADC's (antibody-drug conjugates) for cancer and other diseases.

Immunogen web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INCY
 INO
 INTC
 ISRG
 MCHP
 MYL
 PLX
 REGN
 SGEN
 TTPH
 VBLT
 VSTM
 XLNX
 XLRN
 

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2017 William P. Meyers